JP6680760B2 - アンタゴニストｉｃ ｐｄ−１アプタマー及びその癌治療関連用途への応用 - Google Patents

アンタゴニストｉｃ ｐｄ−１アプタマー及びその癌治療関連用途への応用 Download PDF

Info

Publication number
JP6680760B2
JP6680760B2 JP2017505552A JP2017505552A JP6680760B2 JP 6680760 B2 JP6680760 B2 JP 6680760B2 JP 2017505552 A JP2017505552 A JP 2017505552A JP 2017505552 A JP2017505552 A JP 2017505552A JP 6680760 B2 JP6680760 B2 JP 6680760B2
Authority
JP
Japan
Prior art keywords
aptamer
seq
nucleic acid
aptamers
dimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017505552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523781A5 (enExample
JP2017523781A (ja
Inventor
パン−チィ ヤーン
パン−チィ ヤーン
イー−チューン チャーン
イー−チューン チャーン
ウエイ−ユイン ライ
ウエイ−ユイン ライ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of JP2017523781A publication Critical patent/JP2017523781A/ja
Publication of JP2017523781A5 publication Critical patent/JP2017523781A5/ja
Application granted granted Critical
Publication of JP6680760B2 publication Critical patent/JP6680760B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017505552A 2014-07-31 2015-07-31 アンタゴニストｉｃ ｐｄ−１アプタマー及びその癌治療関連用途への応用 Expired - Fee Related JP6680760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031427P 2014-07-31 2014-07-31
US62/031,427 2014-07-31
PCT/US2015/043162 WO2016019270A1 (en) 2014-07-31 2015-07-31 An antagonistic pd-1 aptamer and its applications in cancer therapy related applications

Publications (3)

Publication Number Publication Date
JP2017523781A JP2017523781A (ja) 2017-08-24
JP2017523781A5 JP2017523781A5 (enExample) 2018-09-13
JP6680760B2 true JP6680760B2 (ja) 2020-04-15

Family

ID=55218360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505552A Expired - Fee Related JP6680760B2 (ja) 2014-07-31 2015-07-31 アンタゴニストｉｃ ｐｄ−１アプタマー及びその癌治療関連用途への応用

Country Status (8)

Country Link
US (1) US10329570B2 (enExample)
EP (1) EP3174985A4 (enExample)
JP (1) JP6680760B2 (enExample)
KR (1) KR20170055474A (enExample)
CN (1) CN107002083A (enExample)
CA (1) CA2956718A1 (enExample)
TW (1) TWI703214B (enExample)
WO (1) WO2016019270A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2711380C2 (ru) 2015-07-16 2020-01-16 Байоксэл Терапьютикс, Инк. Новый подход к лечению рака с применением иммуномодуляции
WO2017143150A1 (en) 2016-02-19 2017-08-24 City Of Hope Bi-specific aptamer
MX2019002618A (es) * 2016-09-06 2019-09-09 The Methodist Hospital System Aptameros especificos para pd 1.
JP7560821B2 (ja) * 2016-09-16 2024-10-03 デューク ユニバーシティ フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法
CN107794267B (zh) * 2017-03-14 2021-03-26 湖南大学 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物
AU2018314236B2 (en) 2017-08-11 2025-02-06 Apterna Limited RNA aptamers against transferrin receptor (TfR)
US11007211B2 (en) 2018-01-07 2021-05-18 City Of Hope CCR7 aptamers and uses thereof
EP3683310A1 (en) 2019-01-21 2020-07-22 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer and use of the aptamer in the diagnosis and treatment of cancer
CN111154765B (zh) * 2019-12-30 2023-08-01 广西医科大学 T细胞免疫检查点pd-1的适配体筛选、鉴定方法及抗肿瘤应用
MX2022010955A (es) 2020-03-03 2022-10-07 Array Biopharma Inc Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida.
CN111593053B (zh) * 2020-05-27 2022-02-15 武汉大学 识别人程序性死亡受体1的dna适配体及方法和应用
EP4419112A4 (en) * 2021-10-22 2025-08-27 Ohio State Innovation Foundation IMMUNOTHERAPY FOR CANCER TREATMENT

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1997031012A1 (en) * 1996-02-22 1997-08-28 The Regents Of The University Of Michigan Gene specific universal mammalian sequence-tagged sites
US20040241651A1 (en) * 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2006516151A (ja) * 2002-11-21 2006-06-22 アーケミックス コーポレイション 改良された薬力学的特性を有する多価アプタマー治療剤ならびにそれらの作製方法および使用法
EP1620547B1 (en) * 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
RS20080075A (sr) * 2005-08-26 2009-07-15 Archemix Corp., Aptameri koji vezuju trombin sa visokim afinitetom
EP2023940B1 (en) * 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
US8835111B2 (en) * 2009-03-12 2014-09-16 Brainco Biopharma S.L. Genotyping tool for improving the prognostic and clinical management of MS patients
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
EP2354247A1 (en) * 2010-02-11 2011-08-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for typing a sample for rheumatoid arthritis or spondyloarthritis
US20140148503A1 (en) * 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
US10023876B2 (en) * 2012-02-16 2018-07-17 Syngenta Participations Ag Engineered pesticidal proteins
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
CA2873797A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating utrn expression
EP2912182B1 (en) * 2012-10-23 2021-12-08 Caris Science, Inc. Aptamers and uses thereof
EP2914722A1 (en) * 2012-11-05 2015-09-09 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies
EP2922861A4 (en) * 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
US11254933B2 (en) * 2014-07-14 2022-02-22 The Regents Of The University Of California CRISPR/Cas transcriptional modulation

Also Published As

Publication number Publication date
US10329570B2 (en) 2019-06-25
CN107002083A (zh) 2017-08-01
WO2016019270A8 (en) 2016-04-14
CA2956718A1 (en) 2016-02-04
US20170218369A1 (en) 2017-08-03
KR20170055474A (ko) 2017-05-19
TWI703214B (zh) 2020-09-01
TW201617449A (zh) 2016-05-16
WO2016019270A1 (en) 2016-02-04
EP3174985A1 (en) 2017-06-07
JP2017523781A (ja) 2017-08-24
EP3174985A4 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
JP6680760B2 (ja) アンタゴニストｉｃ ｐｄ−１アプタマー及びその癌治療関連用途への応用
EP3344772B1 (en) Antagonistic pdl1 aptamers and their applications in cancer therapy
JP6702938B2 (ja) アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用
JP2021521806A (ja) Ｔｎｆ関連炎症性疾患を治療または診断するｔｎｆ指向性アプタマーおよびその使用
US9376490B2 (en) Treatment of inflammatory pain using IL-20 antagonists
TWI831792B (zh) 靶向淋巴細胞活化基因3(lag-3)的核酸適體及其用途
US12409208B2 (en) Treating tissue fibrosis with interleukin 24
US10413564B2 (en) Compositions and methods for combating drug-resistant cancers
WO2016172082A1 (en) A therapeutic gene cocktail for heart regeneration
TW202408575A (zh) 奧布替尼與ｔａｆａｓｉｔａｍａｂ聯合用藥治療
US20170348389A1 (en) Treating liver diseases with interleukin 24

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200319

R150 Certificate of patent or registration of utility model

Ref document number: 6680760

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees